A5023027543- Glutathione Transferases and Polymorphisms
- Bioactive Compounds and Antitumor Agents
- Cell death mechanisms and regulation
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- Synthesis and biological activity
- Peptidase Inhibition and Analysis
- Tannin, Tannase and Anticancer Activities
- Cancer-related Molecular Pathways
- Nanoplatforms for cancer theranostics
- Ubiquitin and proteasome pathways
- Mechanisms of cancer metastasis
- Cancer, Hypoxia, and Metabolism
- T-cell and B-cell Immunology
- Computational Drug Discovery Methods
- Synthesis and Characterization of Heterocyclic Compounds
- Brain Metastases and Treatment
- Virus-based gene therapy research
- Cancer Mechanisms and Therapy
University of California, San Diego
2016-2025
Moores Cancer Center
2015-2025
UC San Diego Health System
2017-2024
University College London
2024
Roland Hill (United Kingdom)
2024
Institute of Infection and Immunity
2024
Entertainment Industry Foundation
2009-2023
New York University
2009-2023
AstraZeneca (United Kingdom)
2015
Cornell University
2004
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management breast cancer. treatment landscape metastatic cancer is evolving constantly. therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number options, if one option fails, there usually another line therapy available, providing meaningful improvements survival. This Insights report focuses on recent updates...
Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer include recommendations clinical management of patients carcinoma situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall systemic therapy (preoperative adjuvant) options nonmetastatic cancer. For full...
Abstract Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However, <50% of patients an objective response, nearly all develop resistance during To elucidate the underlying mechanisms, we constructed interpretable deep learning model response to palbociclib, a CDK4/6i, based on reference map multiprotein assemblies in cancer. The identifies eight core that integrate rare common alterations across 90 genes stratify palbociclib-sensitive versus...
The RAS/RAF/MEK/ERK signaling pathway has been targeted with a number of small molecule inhibitors in oncology clinical development across multiple disease indications. Importantly, cell lines acquired resistance to B-RAF and MEK have shown maintain sensitivity ERK1/2 inhibition by inhibitors. There are selective, noncovalent reported along the promiscuous hypothemycin (and related analogues) that act via covalent mechanism action. This article reports identification series highly selective...
We previously reported that expression of NRIF3 (nuclear receptor interacting factor-3) rapidly and selectively leads to apoptosis breast cancer cells. DIF-1 (also known as interferon regulatory factor-2 binding protein 2 [IRF-2BP2]), the cellular target NRIF3, was identified a transcriptional repressor, knockdown cells but not other cell types. Here, we identify IRF-2BP1 EAP1 (enhanced at puberty 1) important components complex mediating both stability repression. This interaction DIF-1,...
Abstract Self-sufficiency (autonomy) in growth signaling, the earliest recognized hallmark of cancer, is fueled by tumor cell's ability to “secrete-and-sense” factors (GFs); this translates into cell survival and proliferation that self-sustained autocrine/paracrine secretion. A Golgi-localized circuitry comprised two GTPase switches has recently been implicated orchestration signaling autonomy. Using breast cancer cells are either endowed or impaired (by gene editing) their assemble for...
Recent studies suggest a functional involvement of Epithelial-Mesenchymal Transition (EMT) in tumor chemoresistance. Specifically, EMT is associated with chemoresistance and poor prognosis triple-negative breast cancer. However, no effective therapy targeting has been developed. Here, we report that periostin, an extracellular matrix protein, was induced upon chemotherapy tightly correlated the gene signature In cancer xenografts, upregulated periostin expression cells, triggered expansion...
Abstract The rapid evolution of machine learning has led to a proliferation sophisticated models for predicting therapeutic responses in cancer. While many these show promise research, standards clinical evaluation and adoption are lacking. Here, we propose seven hallmarks by which predictive oncology can be assessed compared. These Data Relevance Actionability, Expressive Architecture, Standardized Benchmarking, Generalizability, Interpretability, Accessibility Reproducibility, Fairness....
Abstract Age is a major risk factor for breast cancer. However, the mechanisms by which age affects cancer initiation and progression not fully understood. Unfortunately, there paucity of mouse with to study role aging in cancer, especially impact on epithelial tumor cells-of-origin. To address this we established model was induced de novo young old wildtype mice through intraductal injection lentivirus carrying oncogene HER2/neu. Consistent human data, tumors grew more rapidly than mice....
2561 Background: The potential of immune checkpoint inhibition (ICI) therapy is constrained by the inability to predict patient response. Circulating tumor DNA (ctDNA) has emerged as a promising tool for real-time response tracking and early prediction therapeutic outcomes. However, clinical utility ctDNA-based liquid biopsy faces critical challenge: reliable detection in low-shedding tumors during dramatic responses when ctDNA levels approach analytical threshold. We overcome this technical...
e13043 Background: Leptomeningeal carcinomatosis (LMC) is a rare consequence of metastatic breast cancer (MBC) with dismal prognosis, historical 15-week median overall survival (OS). There no standard care treatment (tx), and paucity data on MBC subtype specific incidence prognosis. The impact newer CNS penetrating systemic (sys) tx like antibody drug conjugates (ADCs) multimodal BC related LMC prognosis underreported in contemporary literature. Here, we present real-world analysis cohort...
Abstract Expression of the nuclear receptor interacting factor 3 (NRIF3) coregulator in a wide variety breast cancer cells selectively leads to rapid caspase-2–dependent apoptotic cell death. A novel death domain (DD1) was mapped 30–amino acid region NRIF3. Because cytotoxicity NRIF3 and DD1 seems be type–specific, these studies suggest that contain “death switch” can specifically modulated by or DD1. Using an MCF-7 cDNA library yeast two-hybrid screen, we cloned mediates apoptosis refer...
Abstract Purpose of Review Triple-negative breast cancer (TNBC) is a heterogeneous disease group with known aggressive phenotype and poor prognosis. To date, it remains challenging given its lack oncogenic targets as seen in hormone receptor + or HER2 cancers, limited efficacy traditional chemotherapy. This article review the latest key literature management metastatic TNBC offers glimpse ongoing drug development. Recent Findings paradigm-shifting trials led to incorporation immune...
Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic form of that lacks an effective targeted therapy. To identify new therapeutic targets, we investigated the phosphohistidine phosphatase, LHPP, which has been implicated in development several types cancer. However, full significance LHPP progression remains unclear due to our limited understanding its molecular mechanism. We found levels phosphatase were significantly increased human patients compared normal adjacent...
Expression of NRIF3 (Nuclear Receptor Interacting Factor-3) rapidly and selectively leads to apoptosis breast cancer cells. This occurs through binding or its 30 amino acid Death Domain-1 (DD1) region the transcriptional repressor, DIF-1 (DD1 Factor-1). acts in a wide variety cells but not other cell types repress pro-apoptotic gene, FASTKD2. DD1 inactivates repressor leading rapid derepression FASTKD2, which initiates within 5–8 h expression. Although FASTKD2 is an inner mitochondrial...
e13117 Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that revolutionized the management of patients with HER2+ (HER2 FISH+, IHC 3+) and HER2 low FISH-, 1+/2+) metastatic breast cancer (MBC). Studies have shown T-DXd may induce antitumor activity in MBC brain metastases (BM). However, data limited on central nervous system (CNS) efficacy disease. The only report thus far from cohorts DEBBRAH study 12 showing intracranial overall response rate (ORR-IC) 50%...